文献速递心外重症与机械循环支持

患者特异性血管性血友病因子降解严重程度可识别出血高风险左心室辅助装置患者

Patient-specific severity of von Willebrand factor degradation identifies patients with a left ventricular assist device at high risk for bleeding.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-03-30

前瞻性纵向队列研究纳入67例连续流左心室辅助装置患者,比较出血与未出血者的血管性血友病因子多聚体及凝血功能,构建全因出血风险评分和消化道出血风险评分,两评分对装置相关出血均有较高预测价值。

要点

  • 连续流左心室辅助装置支持显著降低高分子量血管性血友病因子多聚体(P < .001)。
  • 出血者高分子量血管性血友病因子多聚体丢失大于未出血者(-10 ± 5% vs -7 ± 4%,P = .008)。
  • 全因出血风险评分区分出血与未出血者(86 ± 56% vs 41 ± 48%,P < .001),阳性预测值86%。

核心结论

  • 血管性血友病因子多聚体丢失及凝血功能降低的严重程度所生成的出血风险评分对左心室辅助装置相关出血具有较高预测价值,该模型可能指导个体化抗血栓治疗和患者监测。

研究设计与样本

  • 前瞻性纵向队列研究,纳入67例连续流左心室辅助装置患者,在装置支持前及支持期间采集配对血样。
  • 随访640 ± 395天后,患者被分为全因出血者、消化道出血者和未出血者。
  • 评估血管性血友病因子多聚体和血管性血友病因子凝血功能以确定出血风险。

主要发现

  • 67例患者中,34例(51%)发生出血,26例(39%)发生消化道出血,33例(49%)未出血。
  • 所有患者中,左心室辅助装置支持显著降低高分子量血管性血友病因子多聚体(P < .001)。
  • 出血者高分子量血管性血友病因子多聚体丢失大于未出血者(均值±标准差,-10 ± 5% vs -7 ± 4%,P = .008)。
  • 出血者血管性血友病因子凝血功能降低大于未出血者(中位数[四分位距],-12% [-31%至4%] vs 0% [-9至26%],P = .01)。

关键数值与推荐

  • 全因出血风险评分区分出血者与未出血者(86 ± 56% vs 41 ± 48%,P < .001),阳性预测值86%(95%CI,66%-95%),诊断比值比11(95%CI,2.9-44)。
  • 消化道出血风险评分区分消化道出血者与未出血者(202 ± 114 vs 120 ± 86,P = .003),阳性预测值88%(64%-97%),诊断比值比18(3.1-140)。

临床怎么用

  • 作者认为该模型可能指导个体化抗血栓治疗和患者监测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Continuous-flow left ventricular assist devices (LVADs) cause an acquired von Willebrand factor (VWF) deficiency and bleeding. Models to risk-stratify for bleeding are urgently needed. We developed a model of continuous-flow LVAD bleeding risk from patient-specific severity of VWF degradation. METHODS: In a prospective, longitudinal cohort study, paired blood samples were obtained from patients (n = 67) with a continuous-flow LVAD before and during support. After 640 ± 395 days, patients were categorized as all-cause bleeders, gastrointestinal (GI) bleeders, or nonbleeders. VWF multimers and VWF clotting function were evaluated to determine bleeding risk. RESULTS: Of 67 patients, 34 (51%) experienced bleeding, 26 (39%) experienced GI bleeding, and 33 (49%) did not bleed. In all patients, LVAD support significantly reduced high-molecular-weight VWF multimers (P < .001). Bleeders exhibited greater loss of high-molecular-weight VWF multimers (mean ± standard deviation, -10 ± 5% vs -7 ± 4%, P = .008) and reduced VWF clotting function versus nonbleeders (median [interquartile range], -12% [-31% to 4%] vs 0% [-9 to 26%], P = .01). A combined metric of VWF multimers and VWF function generated the All-Cause Bleeding Risk Score, which stratified bleeders versus nonbleeders (86 ± 56% vs 41 ± 48%, P < .001) with a positive predictive value of 86% (95% confidence interval, 66%-95%) and diagnostic odds ratio of 11 (95% confidence interval, 2.9-44). A separate GI Bleeding Risk Score stratified GI bleeders versus nonbleeders (202 ± 114 vs 120 ± 86, P = .003) with a positive predictive value of 88% (64%-97%) and diagnostic odds ratio of 18 (3.1-140). CONCLUSIONS: The severity of loss of VWF multimers and VWF clotting function generated Bleeding Risk Scores with high predictive value for LVAD-associated bleeding. This model may guide personalized antithrombotic therapy and patient surveillance.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hennessy-Strahs S, Kang J, Krause E, et al. Patient-specific severity of von Willebrand factor degradation identifies patients with a left ventricular assist device at high risk for bleeding. J Thorac Cardiovasc Surg. 2022. PMID: 35501195. doi:10.1016/j.jtcvs.2022.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。